These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32023369)

  • 21. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
    Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
    J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing of Drugs-The Ketamine Story.
    Das J
    J Med Chem; 2020 Nov; 63(22):13514-13525. PubMed ID: 32915563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
    McGirr A; Berlim MT; Bond DJ; Fleck MP; Yatham LN; Lam RW
    Psychol Med; 2015 Mar; 45(4):693-704. PubMed ID: 25010396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ketamine in the Treatment of Depressive Episodes.
    Ritter P; Findeis H; Bauer M
    Pharmacopsychiatry; 2020 Mar; 53(2):45-50. PubMed ID: 31434140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
    Szymkowicz SM; Finnegan N; Dale RM
    J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
    Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
    J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine for depression clinical issues.
    Iqbal SZ; Mathew SJ
    Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
    Swainson J; McGirr A; Blier P; Brietzke E; Richard-Devantoy S; Ravindran N; Blier J; Beaulieu S; Frey BN; Kennedy SH; McIntyre RS; Milev RV; Parikh SV; Schaffer A; Taylor VH; Tourjman V; van Ameringen M; Yatham LN; Ravindran AV; Lam RW
    Can J Psychiatry; 2021 Feb; 66(2):113-125. PubMed ID: 33174760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of ketamine as an antidepressant: a systematic review and meta-analysis.
    Coyle CM; Laws KR
    Hum Psychopharmacol; 2015 May; 30(3):152-63. PubMed ID: 25847818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
    Smith-Apeldoorn SY; Vischjager M; Veraart JK; Kamphuis J; Aan Het Rot M; Schoevers RA
    J Psychopharmacol; 2022 May; 36(5):531-544. PubMed ID: 35546042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
    Sanders B; Brula AQ
    J Psychiatr Res; 2021 May; 137():29-35. PubMed ID: 33647726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.